Other News To Note
Wednesday, June 27, 2012
Gentium SpA, of Villa Guardia, Italy, said it submitted its responses to the Day 180 list of outstanding issues received from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.